Single cell transcriptome profiling of kidney cell populations and the effect of liraglutide in diabetes. Single cell transcriptome profiling of kidney cell populations and the effect of liraglutide in diabetes

While incretin-based therapies are known to improve glucose control in diabetes, growing evidence suggests a glucose-independent mechanism in protection against kidney disease. To further investigate incretin effects in kidney, we examined long-term therapy with liraglutide, a Glucagon-like peptide 1 receptor (GLP1R) agonist, in diabetic (Ins2Akita) and control mice and profiled renal cell transcriptomes using single-cell sequencing. Overall design: Control and diabetic (C57BL/6 - Ins2Akita/J ) mice treated with liraglutide were monitored over a 20 week study period, followed by scRNA-seq analysis of dissociated aortae using the Drop-Seq platform from Dolomite Bio.